Targets › FDG
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jun 2030.
Open in Phaseline: the race on FDG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Akiva Mintz | 18F-FDG Fluorine-18 fluorodeoxyglucose (18F-FDG) is a radioactive glucose analog used as a metabol | FDG | Phase 2 | Healthy Volunteer | Jun 2030 |
Healthy Volunteer (1)
small molecule (1)
Akiva Mintz (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.